Aligos Therapeutics Inc. (5WK0)

Overview

Aligos Therapeutics, Inc. is a pioneering clinical-stage biopharmaceutical company that embarks on the mission of developing novel therapeutics aimed at fulfilling the unmet medical needs prevalent in viral and liver diseases. Incorporated in 2018 and based in South San Francisco, California, the company strategically focuses its efforts on the invention and progression of treatments that could potentially alter the current therapeutic landscape. By engrossing in research and development activities, Aligos Therapeutics is at the forefront of addressing complex health issues, particularly in the domain of non-alcoholic steatohepatitis (NASH), chronic hepatitis B (CHB), and coronavirus-related conditions. Engaging in a series of collaboration agreements with leading academic and corporate entities, the company reinforces its scientific and commercial footprint across the globe, signifying a substantial commitment towards fostering innovative healthcare solutions.

Products and Services

• ALG-055009

  A hallmark of Aligos Therapeutics’ portfolio, ALG-055009 emerges as a small molecule THR-ß agonist currently under evaluation in a Phase 2a clinical trial. This cutting-edge therapeutic candidate is specifically designed to treat non-alcoholic steatohepatitis (NASH), marking a significant stride towards addressing this challenging liver disease.

• ALG-000184

  This innovative capsid assembly modulator has successfully completed a Phase 1b clinical trial, showcasing its potential in the treatment of chronic hepatitis B (CHB). As a testament to the company’s dedication to combating viral liver diseases, ALG-000184 exemplifies a proactive approach to CHB therapy.

• ALG-125755

  In the realm of RNA-based therapeutics, ALG-125755 stands out as a siRNA (small interfering RNA) drug candidate. Currently assessed in a Phase I clinical trial, this product targets chronic hepatitis B (CHB), reinforcing Aligos Therapeutics’ commitment to leveraging cutting-edge biotechnology for disease management.

• ALG-097558

  Reflecting a versatile and responsive R&D strategy, ALG-097558 is an investigational drug poised in a Phase 2 clinical trial aimed at treating coronavirus. This intervention underscores the company’s agile response to emergent global health crises and its dedication to public health.

Integral to its innovative framework, Aligos Therapeutics has forged strategic partnerships and licensing agreements. Collaborations with entities such as Merck for oligonucleotide therapy in NASH, Emory University for HBV capsid assembly modulator technology, Luxna Biotech for HBV genome-targeting oligonucleotides, and Katholieke Universiteit Leuven for coronavirus protease inhibitors, alongside a clinical partnership with Xiamen Amoytop Biotech, amplify the company’s research capacity and commercial potential in addressing complex viral and liver diseases.